Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?

作     者：Theodora Mourtzi Ilias Kazanis Theodora Mourtzi;Ilias Kazanis

作者机构：Laboratory of Developmental BiologyDepartment of BiologyUniversity of PatrasPatrasGreece 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2022年第17卷第12期

页      面：2637-2642页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100204[医学-神经病学] 10[医学] 

主　　题：endogenous neurodegenerative disease neurogenesis neurotrophic factors Parkinson’s disease stem cells transdifferentiation transplantations 

摘      要：Parkinson’s disease is the second most common neurodegenerative disease and has currently no effective treatment,one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars *** addition,Parkinson’s disease diagnosis is typically done when a significant percentage of the dopaminergic neurons is already *** neurodegenerative disorders,some therapeutic strategies could be effective only at inhibiting further degeneration;on the other hand,cell replacement therapies aim at replacing lost neurons,an approach that would be ideal for the treatment of Parkinson’s *** cell replacement therapies have been tested since the 1970s in the field of Parkinson’s disease;however,there are still significant limitations prohibiting a successful clinical *** the first fetal midbrain intrastriatal graft to the most recent conversion of astrocytes into dopaminergic neurons,we have gained equally,significant insights and questions still looking for an *** review aims to summarize the main milestones in cell replacement approaches against Parkinson’s *** focusing on achievements and failures,as well as on the additional research steps needed,we aim to provide perspective on how future cell replacement therapies treats Parkinson’s disease.